Webuild continues to target a full-year book-to-bill ratio--a measure of orders received relative to the amount billed--greater than 1, revenue of more than 11 billion euros, and earnings before ...

The pullback in U.S. stocks was advancing in Thursday afternoon trade, with the Dow and S&P 500 touching new session lows. The Dow Jones Industrial Average was down about 123 points, or 0.3%, near 43, ...

Hindustan Unilever Ltd. 500696 shares dropped 3.07% to 2,389.05 Indian rupees Thursday, on what proved to be an all-around ...

U.S. stocks ended lower on Thursday, putting a little more daylight between them and record territory claimed earlier in the week. Investors have been focused on what Donald Trump's second ...

Nvidia Corp. may be the top dog on Wall Street in terms of market value, but in the eyes of the 128-year-old Dow Jones ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Small-cap stocks on Thursday were poised to give back more of their gains seen since last week's presidential election. The Russell 2000 index was heading for a third straight day of losses, while ...

Shares of Medicus Pharma tumbled 39%, to $2.50, on the company's first day of trading Thursday. The biotechnology and life-sciences pharmaceutical company on Wednesday said it would sell 970,000 units ...

Shares of a large exchange-traded fund that invests in equities in emerging markets were falling Thursday afternoon, deepening its recent slide. Vanguard FTSE Emerging Markets ETF was declining 0.3% ...

Shares of power producers fell, but not by as much as the broad market, as traders sought out defensive safe havens in light of renewed volatility. American Electric Power said it has an agreement in ...

Oncternal Therapeutics plans to cut its workforce by Dec. 2, leaving only four employees in part-time roles as the company explores strategic options.

U.S. stocks ended lower on Thursday, putting a little more daylight between them and the record territory claimed earlier in the week. Investors have been focused on what Donald Trump's second ...